tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Retrognathia D063173 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Scorpion Stings D065008 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tai J et al. In vivo function of pig islet xenografts in immunosuppressed diabetic mice. 1995 Transplant. Proc. pmid:8539968
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Jonas S et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. 1995 Clin Transplant pmid:8541635
Andoh TF et al. Functional and structural characteristics of experimental FK 506 nephrotoxicity. 1995 Clin. Exp. Pharmacol. Physiol. pmid:8542679
Chaudhuri B et al. The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. 1995 FEBS Lett. pmid:7528690
Sandborn WJ et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. 1995 Hepatology pmid:7528712
Richter A et al. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. 1995 Biochem. Pharmacol. pmid:7531976
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Hemenway CS et al. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 1995 Genetics pmid:8582630
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Gonschior AK et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. 1995 Ther Drug Monit pmid:8585114
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Büttemeyer R et al. Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. 1995 Ann Plast Surg pmid:8585683
Bismuth H Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533415
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Bakhtiar R and Stearns RA Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. 1995 Rapid Commun. Mass Spectrom. pmid:7535601
Ikeda H and Fujiwara K Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. 1995 Hepatology pmid:7535735
Grimmond S et al. Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. 1995 Hum. Genet. pmid:7535744
Kelly PA et al. Tacrolimus: a new immunosuppressive agent. 1995 Am J Health Syst Pharm pmid:7552894
MacDonald AS and Sketris IS Tacrolimus in transplantation. 1995 Am J Health Syst Pharm pmid:7552906
Holmes JA and Twentyman PR The activity of deoxyspergualin in multidrug-resistant cells. 1995 Cancer Chemother. Pharmacol. pmid:7554042
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Elitsur Y et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. 1995 Dig. Dis. Sci. pmid:7555446
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Kobayashi I et al. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. 1995 Eur. J. Pediatr. pmid:7556338
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Woodle ES et al. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. 1995 Clin Transplant pmid:7537988
Mills RA et al. Topical FK-506 prevents experimental corneal allograft rejection. 1995 Cornea pmid:7538061
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Ishikawa A et al. [A case of tacrolimus-induced glucose intolerance following renal allografting]. 1995 Hinyokika Kiyo pmid:7544064
Bennett WM The nephrotoxicity of immunosuppressive drugs. 1995 Clin. Nephrol. pmid:7540121
Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. 1995 Biochem. Biophys. Res. Commun. pmid:7544122
Moro A et al. Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. 1995 EMBO J. pmid:7540135
Zweifach A and Lewis RS Slow calcium-dependent inactivation of depletion-activated calcium current. Store-dependent and -independent mechanisms. 1995 J. Biol. Chem. pmid:7540169
Brand PL and Brus F Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540240
Natazuka T et al. Immunosuppressive drugs and hypertrophic cardiomyopathy. 1995 Lancet pmid:7540241
Matsuo S and Okamoto K Enhancement of FK-506 activities by ganglioside (GM3) in vivo. 1995 Life Sci. pmid:7545772
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Okamoto M et al. In situ proliferating status of mononuclear cells in rat small bowel grafts. 1995 Int J Exp Pathol pmid:7547442
Sakane T et al. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. 1995 Ryumachi pmid:8594659
Hammond TG and Kind CN Pancreatic and nephrotoxicity of immunomodulator compounds. 1995 Toxicol. Lett. pmid:8597171
Karanam BV et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. 1994 Sep-Oct Drug Metab. Dispos. pmid:7530623
Cacciarelli TV et al. Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. 1994 Oct-Dec ASAIO J. pmid:7532042
Ryffel B et al. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. 1994 Nov-Dec Exp. Nephrol. pmid:7532090
Kay AB Immunosuppressive agents in chronic severe asthma. 1994 May-Jun Allergy Proc pmid:7523242
von Asmuth EJ et al. IL-6, IL-8 and TNF production by cytokine and lipopolysaccharide-stimulated human renal cortical epithelial cells in vitro. 1994 May-Jun Eur. Cytokine Netw. pmid:7524716
Yoshida Y et al. Comparison of cardiac rejection in heart and heart-lung concordant xenotransplantation. 1994 Mar-Apr J. Heart Lung Transplant. pmid:7518252
Assan R et al. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. 1994 Jan-Feb Diabete Metab pmid:7520007
Perotti BY et al. FK 506 metabolism in male and female rat liver microsomes. 1994 Jan-Feb Drug Metab. Dispos. pmid:7512020
Akita K et al. Effect of FK506 and anti-CD4 therapy on fetal pig pancreas xenografts and host lymphoid cells in nod/Lt, CBA, and BALB/c mice. 1994 Jan-Feb Cell Transplant pmid:7512875
Yasunami Y et al. Donor-specific unresponsiveness induced by intraportal grafting and FK506 in rat islet allografts: importance of low temperature culture and transplant site on induction and maintenance. 1994 Jan-Feb Cell Transplant pmid:7512876
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Kraus-Friedmann N and Feng L Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. 1994 Biochem. Pharmacol. pmid:7529023
Ohtsuka S et al. Experimental rat pancreas transplant: surgical technique and immunological considerations. 1994 Surg. Today pmid:7516209
Cardenas ME et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 1994 EMBO J. pmid:7529175
Hisatomi K et al. Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation. 1994 Surg. Today pmid:7516210
Kawano K et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia. 1994 Eur Surg Res pmid:7516291
Wolter K et al. Interaction between FK 506 and clarithromycin in a renal transplant patient. 1994 Eur. J. Clin. Pharmacol. pmid:7532134
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Pruschy MN et al. Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. 1994 Chem. Biol. pmid:9383386
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Cakaloglu Y et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. 1994 Hepatology pmid:7519161
Luan S et al. Light-regulated, tissue-specific immunophilins in a higher plant. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7508125
Blazar BR et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. 1994 J. Immunol. pmid:7519216
Tze WJ et al. Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study. 1994 Metab. Clin. Exp. pmid:7510012
Yamauchi T [Multiple abdominal organ transplantation in swine using FK-506]. 1994 Nihon Geka Gakkai Zasshi pmid:7510015
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Nozaki S et al. Effect of brequinar sodium on accelerated cardiac allograft rejection in presensitized recipients. 1994 Transplant. Proc. pmid:7520633
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Calne RY Immunosuppression in liver transplantation. 1994 N. Engl. J. Med. pmid:7523947
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
Connolly JO et al. Renal arteriopathy associated with FK 506 therapy following liver transplantation. 1994 Nephrol. Dial. Transplant. pmid:7526278
Pham SM et al. Cardiac transplantation at the University of Pittsburgh: 1994 update. 1994 Clin Transpl pmid:7547531
Radanyi C et al. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7526392
Abu-Elmagd K et al. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. 1994 Clin Transpl pmid:7547533
Ericzon B et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. 1994 Transpl. Int. pmid:11271178
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Yano S et al. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes. 1994 Jpn. J. Cancer Res. pmid:7511575